Profile data is unavailable for this security.
About the company
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
- Revenue in USD (TTM)0.00
- Net income in USD57.92m
- Incorporated2024
- Employees17.00
- LocationTevogen Bio Holdings Inc15 Independence Boulevard, Suite 410WARREN 07059United StatesUSA
- Phone+1 (646) 807-8832
- Fax+1 (302) 655-5049
- Websitehttps://tevogen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IO Biotech Inc | 0.00 | -88.00m | 74.45m | 68.00 | -- | 0.7733 | -- | -- | -1.44 | -1.44 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -76.85 | -- | -86.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
Omega Therapeutics Inc | 6.31m | -78.90m | 75.56m | 93.00 | -- | 2.88 | -- | 11.97 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
Genelux Corp | 8.00k | -26.54m | 76.67m | 23.00 | -- | 2.01 | -- | 9,583.59 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
Renovaro Inc | 0.00 | -88.12m | 76.70m | 11.00 | -- | 0.4549 | -- | -- | -1.08 | -1.08 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -60.56 | -27.81 | -68.21 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
PMV Pharmaceuticals Inc | 0.00 | -48.88m | 77.28m | 63.00 | -- | 0.3606 | -- | -- | -0.9662 | -0.9662 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -20.38 | -21.16 | -21.39 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
Sellas Life Sciences Group Inc | 0.00 | -34.44m | 77.84m | 16.00 | -- | 23.99 | -- | -- | -0.934 | -0.934 | 0.00 | 0.0504 | 0.00 | -- | -- | 0.00 | -204.48 | -111.48 | -838.03 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
Tevogen Bio Holdings Inc | 0.00 | 57.92m | 78.50m | 17.00 | 1.22 | -- | -- | -- | 0.3758 | 0.3758 | 0.00 | -0.0452 | 0.00 | -- | -- | 0.00 | 1,217.57 | -- | -- | -- | -- | -- | -- | -- | -- | -702.58 | -- | -- | -- | -- | 99.69 | -- | -- | -- |
Cidara Therapeutics Inc | 31.58m | -116.17m | 79.32m | 69.00 | -- | 0.3933 | -- | 2.51 | -25.49 | -25.30 | 6.95 | 28.66 | 0.2617 | -- | 8.06 | 457,623.20 | -96.27 | -65.23 | -136.45 | -154.37 | 91.14 | -- | -367.91 | -100.61 | -- | -- | 0.0053 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
Adlai Nortye Ltd (ADR) | 5.00m | -54.07m | 79.34m | 127.00 | -- | 1.49 | -- | 15.87 | -6.21 | -6.21 | 0.2465 | 1.45 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -1,081.30 | -- | -- | -- | 0.4255 | -- | -- | -- | -78.38 | -- | -- | -- |
Chimerix Inc | 144.00k | -84.70m | 79.76m | 72.00 | -- | 0.5126 | -- | 553.89 | -0.9507 | -0.9507 | 0.0016 | 1.74 | 0.0007 | -- | 1.86 | 2,000.00 | -40.37 | -30.45 | -44.33 | -34.09 | 10.42 | -- | -58,820.14 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
Anebulo Pharmaceuticals Inc | 0.00 | -9.35m | 79.87m | 2.00 | -- | 16.02 | -- | -- | -0.3633 | -0.3633 | 0.00 | 0.1922 | 0.00 | -- | -- | 0.00 | -91.51 | -- | -104.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
Aileron Therapeutics Inc | 0.00 | -25.22m | 80.81m | 15.00 | -- | 1.44 | -- | -- | -3.25 | -3.25 | 0.00 | 4.67 | 0.00 | -- | -- | 0.00 | -40.88 | -65.99 | -43.02 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Ovid Therapeutics Inc | 567.53k | -29.75m | 81.62m | 40.00 | -- | 0.918 | -- | 143.81 | -0.4218 | -0.4218 | 0.008 | 1.25 | 0.0045 | -- | -- | 14,188.25 | -23.39 | -20.78 | -25.86 | -23.27 | -- | -- | -5,241.56 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
Regencell Bioscience Holdings Ltd | 0.00 | -4.71m | 81.79m | 12.00 | -- | 8.05 | -- | -- | -0.362 | -0.362 | 0.00 | 0.781 | 0.00 | -- | -- | 0.00 | -37.91 | -- | -37.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
Aclaris Therapeutics Inc | 32.02m | -58.68m | 82.05m | 91.00 | -- | 0.613 | -- | 2.56 | -0.8267 | -0.8267 | 0.4509 | 1.88 | 0.1614 | -- | 84.70 | 351,824.20 | -29.58 | -47.29 | -32.76 | -53.87 | 42.63 | 44.00 | -183.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
Holder | Shares | % Held |
---|---|---|
Polar Asset Management Partners, Inc.as of 30 Jun 2024 | 1.99m | 1.16% |
Portland Global Advisors LLCas of 30 Jun 2024 | 1.91m | 1.12% |
Harraden Circle Investments LLCas of 10 Jan 2024 | 838.97k | 0.49% |
Cantor Fitzgerald & Co.as of 30 Jun 2024 | 650.00k | 0.38% |
Geode Capital Management LLCas of 30 Jun 2024 | 340.80k | 0.20% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 208.30k | 0.12% |
New York State Common Retirement Fundas of 30 Jun 2024 | 137.00k | 0.08% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 107.24k | 0.06% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 64.53k | 0.04% |
Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 49.58k | 0.03% |